

# Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/AEB2DCA1318EN.html>

Date: April 2021

Pages: 55

Price: US\$ 125.00 (Single User License)

ID: AEB2DCA1318EN

## Abstracts

Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corp, focuses on the discovery, development, and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection (HBV). Its pipeline includes capsid assembly inhibitors: AB-729, AB-836 and a HBV RNA destabilizer. The company develops product candidates based on its lipid nanoparticle (LNP) delivery technology. Arbutus Biopharma works in partnership and collaboration with Genevant Sciences Inc, Alnylam Pharmaceuticals Inc, Acrotech Biopharma LLC and Gritstone Oncology. It operates in the US and Canada. Arbutus Biopharma is headquartered in Warminster, Pennsylvania, the US.

### Arbutus Biopharma Corp Key Recent Developments

Apr 28,2021: Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

Mar 04,2021: Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

Feb 22,2021: Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

Jan 25,2021: Arbutus announces 2021 corporate objectives and provides financial update

Nov 05,2020: Arbutus reports third quarter 2020 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Arbutus Biopharma Corp - Key Facts  
Arbutus Biopharma Corp - Key Employees  
Arbutus Biopharma Corp - Key Employee Biographies  
Arbutus Biopharma Corp - Major Products and Services  
Arbutus Biopharma Corp - History  
Arbutus Biopharma Corp - Company Statement  
Arbutus Biopharma Corp - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries  
Joint Venture

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Arbutus Biopharma Corp - Business Description  
Business Segment: Non-Cash Royalty Revenue  
Performance  
Business Segment: Revenue from Collaborations and Licenses  
Performance  
R&D Overview  
Arbutus Biopharma Corp - Corporate Strategy  
Arbutus Biopharma Corp - SWOT Analysis  
SWOT Analysis - Overview  
Arbutus Biopharma Corp - Strengths  
Arbutus Biopharma Corp - Weaknesses  
Arbutus Biopharma Corp - Opportunities  
Arbutus Biopharma Corp - Threats  
Arbutus Biopharma Corp - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Arbutus Biopharma Corp, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Apr 28, 2021: Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

Mar 04, 2021: Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

Feb 22, 2021: Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

Jan 25, 2021: Arbutus announces 2021 corporate objectives and provides financial update

Nov 05, 2020: Arbutus reports third quarter 2020 financial results and provides corporate update

Aug 07, 2020: Arbutus reports second quarter 2020 financial results and provides corporate update

May 11, 2020: Arbutus reports first quarter 2020 financial results, provides pipeline update and announces new research initiative to identify novel antiviral therapies for the treatment of coronavirus infections

Mar 05, 2020: Arbutus reports fourth quarter and year end 2019 financial results, confirms 2020 corporate objectives and provides pipeline update

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Arbutus Biopharma Corp, Key Facts  
Arbutus Biopharma Corp, Key Employees  
Arbutus Biopharma Corp, Key Employee Biographies  
Arbutus Biopharma Corp, Major Products and Services  
Arbutus Biopharma Corp, History  
Arbutus Biopharma Corp, Joint Venture  
Arbutus Biopharma Corp, Key Competitors  
Arbutus Biopharma Corp, Ratios based on current share price  
Arbutus Biopharma Corp, Annual Ratios  
Arbutus Biopharma Corp, Annual Ratios (Cont...1)  
Arbutus Biopharma Corp, Interim Ratios  
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Arbutus Biopharma Corp, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Arbutus Biopharma Corp, Performance Chart (2016 - 2020)

Arbutus Biopharma Corp, Ratio Charts

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/AEB2DCA1318EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AEB2DCA1318EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970